PTC Therapeutics reports Q2 2026 revenue of $361 million, raises full-year guidance

PTC Therapeutics announced financial results for the quarter ended June 30, 2026, along with a corporate update, in a press release dated July 30, 2026. The company reported total revenue of $361 million, including $239 million of product revenue.¹

Revenue from the newly launched drug Sephience (sepiapterin) reached $151.3 million for the second quarter of 2026, a 21% increase compared to the first quarter of 2026.¹ Translarna (ataluren) generated $42.2 million in net product revenues, down from $59.5 million in the second quarter of 2025.¹ Emflaza (deflazacort) revenue fell to $24.6 million from $36.4 million a year earlier, which the company attributed to continued generic erosion.¹

On the pipeline side, PTC reported positive results from the votoplam PIVOT-HD long-term extension study, with enrollment ongoing in the global Phase 3 INVEST-HD study.¹ The PIVOT-HD 24-month data showed dose-dependent disease slowing on the cUHDRS scale in Stage 2 participants, reaching 52% at the 10 mg dose level.¹ The INVEST-HD trial is run and financed by partner Novartis, which is aiming to enroll about 770 people with early symptomatic disease.¹ Initiation of that study triggered a $50.0 million milestone payment from Novartis tied to the first patient dosed in the trial.¹

The company also said a study called PROVE-FA, meant to support an NDA resubmission for Friedreich's ataxia treatment vatiquinone, is expected to begin in the third quarter of 2026 and will enroll approximately 120 patients ages 7 to 21.¹

PTC raised its full-year 2026 guidance, now expecting total revenue of $1.18 to $1.28 billion, with product revenue guidance raised to $850 to $950 million from $750 to $850 million.¹ The company reported net income of $83.5 million for the quarter, compared to a net loss of $64.8 million in the second quarter of 2025.¹